Literature DB >> 824368

Detection of complement activation by counterimmunoelectrophoresis (CIE).

C M Arroyave, E M Tan.   

Abstract

Counterimmunoelectrophoresis (CIE) was used as a method of detecting activation of the third component of the complement system (C3). Highly purified C3, normal human serum (NHS), EDTA-treated plasma and serum activated with aggregated human immunoglobulin (agg-IgG) or inulin were used as sources of C3 and/or C3 split products. Activation of the alternative pathway of complement was assayed in the presence of EGTA (10 mM) and MgCl2 (0.3 mM), conditions which block activation of the classical pathway. When purified native C3, fresh NHS and fresh EDTA-plasma were tested in CIE against either antisera to whole C3 or to C3 split products, only one precipitin line was found, which was identified as native C3. However, when serum activated with agg-IgG or inulin were tested against the same reagents, two precipitin lines were seen. The first, with more cathodal mobility was identical to that of native C3. The second line had a more anodal mobility, was distinctly separated from the first and contained C3c and C3d as shown immunochemically with specific antisera. Native C3 and split products of C3 were identified by this CIE method in patients showing evidence of activated complement by having subnormal total complement (CH50) levels. When C3 split products were identified, the C3c-C3d precipitin line could always be distinguished from native C3 by its different electrophoretic mobility, even when C3 concentrations in serum varied from 0.25 mg/ml to 1.5 mg/ml. The sensitivity of CIE was compared to that of CH50 by asssaying at different time intervals after agg-IgG was added to fresh NHS. C3c-C3d split products were detected by CIE before any fall in CH50 and at all times when a significant decrease in CH50 was present. This study shows that the CIE technique is a highly sensitive, specific and rapid method for detecting activation of the complement system via classical or alternative pathways in human disease.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 824368     DOI: 10.1016/0022-1759(76)90148-4

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  14 in total

1.  Complement, complement activation and anaphylatoxins in human ovarian follicular fluid.

Authors:  R Perricone; C de Carolis; C Moretti; E Santuari; G de Sanctis; L Fontana
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

2.  Mechanism of complement activation by radiographic contrast media.

Authors:  C M Arroyave; E M Tan
Journal:  Clin Exp Immunol       Date:  1977-07       Impact factor: 4.330

3.  Immune reactants in cryoproteins. Relationship to complement activation.

Authors:  M R Wilson; C M Arroyave; L Miles; E M Tan
Journal:  Ann Rheum Dis       Date:  1977-12       Impact factor: 19.103

Review 4.  Immune complexes in human diseases: a review.

Authors:  A N Theofilopoulos; F J Dixon
Journal:  Am J Pathol       Date:  1980-08       Impact factor: 4.307

Review 5.  Methods to detect and quantitate complement activation.

Authors:  N R Cooper; G R Nemerow; J T Mayes
Journal:  Springer Semin Immunopathol       Date:  1983

6.  Immunochemical quantitation of complement components of Clq and C3 in sera and synovial fluids of patients with bone and joint diseases.

Authors:  T Ochi; K Yonemasu; K Ono
Journal:  Ann Rheum Dis       Date:  1980-06       Impact factor: 19.103

7.  Clinical applications of immunofixation: detection and quantitation of complement activation.

Authors:  J T Whicher; J Higginson; P G Riches; S Radford
Journal:  J Clin Pathol       Date:  1980-08       Impact factor: 3.411

8.  Component concentrations and activation of the complement system in neonatal illness: a preliminary study of necrotizing enterocolitis.

Authors:  D K Stevenson; Y P Hsu; M McMorrow; C L Berseth; J Neu; J J Miller
Journal:  Eur J Pediatr       Date:  1980-09       Impact factor: 3.183

9.  Clinical application of new technique that measures C4d for assessment of activation of classical complement pathway.

Authors:  E T Davies; B A Nasaruddin; A Alhaq; G Senaldi; D Vergani
Journal:  J Clin Pathol       Date:  1988-02       Impact factor: 3.411

10.  Association of rheumatoid factor with complement activation in rheumatoid arthritis and other diseases.

Authors:  P A Reyes; J G Maluf; J G Curd; J H Vaughan
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.